Is abeta a sufficient biomarker for monitoring anti-abeta clinical studies? A critical review.

ABSTRACT

Amyloid-beta (Aß) in Alzheimer's disease (AD) appeared to be a promising target for disease-modifying therapeutic strategies like passive immunotherapy with anti-Aß monoclonal antibodies (mAbs). Biochemical markers in cerebrospinal fluid (CSF) include alterations of Aß that allow the diagnosis of AD. Biomarker strategies, such as the levels of Aß in CSF and plasma, currently play an important role in early clinical trials for AD. Indeed, these strategies have a relevant impact on the outcome of such studies, since the biomarkers are used to monitor the bioactivity of anti-Aß mAbs. The clinical trials of Solanezumab were mainly based on the readout of Aß levels in CSF and plasma, whereas those of Bapineuzumab were based on cognition; however, little is known about the mechanisms altering these biomarker levels, and no biomarker has yet been proven to be a successful predictor for AD therapy. In addition, the Aß biomarkers allow for the determination of free and bound anti-Aß mAb in order to monitor the available amount of bioactive drug and could give hints to the mechanism of action. In this review, we discuss clinical Aß biomarker data and the latest regulatory strategies.